Literature DB >> 11050081

The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor.

U Maurer1, F Jehan, C Englert, G Hubinger, E Weidmann, H F DeLuca, L Bergmann.   

Abstract

The Wilms' tumor gene (wt1) encodes a transcription factor involved in urogenital development, in particular in renal differentiation, and in hematopoietic differentiation. Differentiation of a number of solid tumor and leukemic cells lines can be mediated by 1,25-dihydroxyvitamin D(3). This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D(3), the vitamin D receptor (VDR). In initial experiments addressing a possible link between WT1 and VDR, we observed a correlated expression of WT1 and VDR mRNA in samples from renal tissues. HT29 colon carcinoma cells, stably transfected to express WT1, exhibited elevated endogenous VDR levels compared with control cells transfected with a control construct. Elevated VDR expression was found in wt1-transfected human embryonic kidney 293 cells, as well. In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1. The responsive sequence element was specifically bound by wild-type, but not by mutated WT1, in electrophoretic mobility shift assays. HT29 colon carcinoma cells, which respond to 1,25-dihydroxyvitamin D(3) with slow induction of growth arrest, were investigated for the influence of WT1 on 1,25-dihydroxyvitamin D(3)-mediated growth suppression. Although HT29 cells transfected with a control construct responded moderately to 1,25-dihydroxyvitamin D(3), the response of HT29 cells expressing WT1 was strikingly enhanced. Stimulation with dihydroxyvitamin D(3) caused an up to 3-fold reduction in the growth rate of different HT29 clones expressing WT1 as compared with control cells lacking WT1 expression. Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D(3). We conclude that the vitamin D receptor gene is a target for transcriptional activation by WT1, suggesting a possible physiological role of this regulatory pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050081     DOI: 10.1074/jbc.M005292200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Common variants at 11p13 are associated with susceptibility to tuberculosis.

Authors:  Thorsten Thye; Ellis Owusu-Dabo; Fredrik O Vannberg; Reinout van Crevel; James Curtis; Edhyana Sahiratmadja; Yanina Balabanova; Christa Ehmen; Birgit Muntau; Gerd Ruge; Jürgen Sievertsen; John Gyapong; Vladyslav Nikolayevskyy; Philip C Hill; Giorgio Sirugo; Francis Drobniewski; Esther van de Vosse; Melanie Newport; Bachti Alisjahbana; Sergey Nejentsev; Tom H M Ottenhoff; Adrian V S Hill; Rolf D Horstmann; Christian G Meyer
Journal:  Nat Genet       Date:  2012-02-05       Impact factor: 38.330

2.  The Wilms' tumor gene Wt1 is required for normal development of the retina.

Authors:  Kay-Dietrich Wagner; Nicole Wagner; Valerie P I Vidal; Gunnar Schley; Dagmar Wilhelm; Andreas Schedl; Christoph Englert; Holger Scholz
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

3.  Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis.

Authors:  Xiaohui Zhang; Pengfei Li; Junying Bao; Santo V Nicosia; Honggang Wang; Steven A Enkemann; Wenlong Bai
Journal:  J Biol Chem       Date:  2005-08-10       Impact factor: 5.157

4.  Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1.

Authors:  Nicole Wagner; Kay-Dietrich Wagner; Heinz Theres; Christoph Englert; Andreas Schedl; Holger Scholz
Journal:  Genes Dev       Date:  2005-11-01       Impact factor: 11.361

5.  Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Authors:  Ayelet Shabtay; Hagar Sharabani; Zeev Barvish; Michael Kafka; Doron Amichay; Joseph Levy; Yoav Sharoni; Milan R Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Oncology       Date:  2008-10-14       Impact factor: 2.935

6.  CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Authors:  Puneet Dhawan; Robert Wieder; Robert Weider; Sylvia Christakos
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

Review 7.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 8.  Regulation of gene expression by WT1 in development and tumorigenesis.

Authors:  Leif W Ellisen
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 9.  The role of WT1 in oncogenesis: tumor suppressor or oncogene?

Authors:  David M Loeb; Saraswati Sukumar
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.